证券代码：000952 证券简称：广济药业 公告编号：2025-055 湖北广济药业股份有限公司 关于公司向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）于 2025 年 10 月 29 日召开第十一届董事会第十二次（临时）会议，审议通过了《关于公司向银行申请综 合授信额度的议案》，具体情况如下： 一、申请综合授信情况 根据生产经营和业务发展需要，公司拟向中国民生银行股份有限公司武汉分行申请 综合授信 15,000 万元，授信期限 1 年（其中中长期流动资金贷款支用额度不超过 1 亿 元，期限不超过 2 年），授信品种为流动资金贷款、银行承兑汇票、银承贴现、国内信 用证、信融 e 等，担保方式为抵押（以公司位于武穴市大金镇张榜村宋煜村刘元村大金 产业园及大金镇武梅路东土地面积 712,063.09 平方米、建筑面积总计 79,354.17 平方 米的土地使用权及不动产抵押权证），年利率不超过 3%。 以上授信额度不等于公司的实际融资金额，实际融资金额及资产抵押情况由公司视 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-054 湖北广济药业股份有限公司 第十一届董事会第十二次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 1、会议通知的时间和方式：会议通知于 2025 年 10 月 20 日以专人送达、书 面传真和电子邮件形式发出； 2、会议的时间和方式：2025 年 10 月 29 日上午 10 点以通讯的方式召开； 3、本次会议应参与表决董事 9 人（含独立董事 3 人），实际参与表决董事 9 人。其中，董事长胡立刚先生因公务原因不能亲自出席本次会议，已授权董事 龚铖先生代为出席并行使表决权。经全体过半数董事推举，由董事龚铖先生代董 事长胡立刚先生主持本次会议； 4、本次会议由董事龚铖先生主持； 表决结果：9 票同意，0 票反对，0 票弃权，议案获得通过。 本议案已经公司第十一届董事会第七次独立董事专门会议审议通过，同意将 该议案提交本次董事会审议。 具体内容详见公司同日在指定媒体上披露的《关于拟为控股子公司广济药业 （孟州）有限公司提供担保的公告》（公告编号：2 ...

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) reported a decline in revenue and significant losses in the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved a revenue of 429 million yuan in the first three quarters, representing a year-on-year decrease of 7.12% [1] - The net profit attributable to the parent company was a loss of 97.3 million yuan [1] - The non-recurring net profit also showed a loss of 101 million yuan [1] - The basic earnings per share were reported at -0.2789 yuan [1]

Core Viewpoint - Guangji Pharmaceutical reported a decline in revenue and a net loss for the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 145 million yuan in the third quarter of 2025, representing a year-on-year decrease of 12.57% [1] - The net profit attributable to shareholders was a loss of 21.7836 million yuan [1] - The basic earnings per share were reported at -0.0628 yuan [1]

Company Performance - Guangji Pharmaceutical reported a revenue of approximately 429 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 7.12% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 97.3 million yuan [1] - The basic earnings per share showed a loss of 0.2789 yuan [1] Market Capitalization - As of the report, Guangji Pharmaceutical's market capitalization stands at 2.4 billion yuan [1]

证券代码：000952 证券简称：广济药业 公告编号：2025-052 湖北广济药业股份有限公司 第十一届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 表决结果：9 票同意，0 票反对，0 票弃权获得通过。 本议案已经公司第十一届董事会第六次审计委员会审议通过，同意将该议案 提交本次董事会审议。 1、会议通知的时间和方式：会议通知于 2025 年 10 月 13 日以专人送达、书 面传真和电子邮件形式发出； 2、会议的时间和方式：2025 年 10 月 23 日上午 10 点在湖北广济药业股份 有限公司（以下简称"公司"）武穴市大金产业园行政楼二楼会议室以现场结合 通讯的方式召开； 3、本次会议应到董事 9 人（含独立董事 3 人），实到董事 9 人，胡立刚先 生、龚铖先生、郭韶智先生、方智先生为现场表决，刘波先生、石守东先生、郭 炜先生、洪葵女士、梅建明先生为通讯表决； 4、本次会议由董事长胡立刚先生主持，全体高级管理人员列席本次会议； 5、本次会议的召开符合《中华人民共和国公司法》和《公司章程》的有关 规定，会议决议合法、有效 ...

Financial Performance - The company's revenue for Q3 2025 was ¥144,907,398.09, representing a decrease of 12.57% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥21,783,561.40, an increase in loss of 58.05% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥23,058,299.19, which is 58.81% worse than the previous year[5]. - The company's basic earnings per share for Q3 2025 was -¥0.0628, a deterioration of 57.71% compared to the same period last year[5]. - The company's operating income for the first nine months of 2025 was ¥429,263,703.57, down 7.12% from ¥462,193,617.06 in the same period last year[10]. - Total revenue for the current period is RMB 429.26 million, a decrease of 7.1% from RMB 462.19 million in the previous period[22]. - The company reported a net profit of -107,028,427.53 yuan, compared to -172,457,181.76 yuan in the previous period, indicating an improvement of approximately 38%[23]. - Operating profit was -105,012,150.37 yuan, an improvement from -170,517,779.03 yuan year-over-year[23]. - The total comprehensive income attributable to the parent company was -97,298,376.26 yuan, compared to -158,577,188.07 yuan in the previous period, showing an improvement of about 39%[24]. - Basic earnings per share were -0.2789, an improvement from -0.4498 in the previous period[24]. Cash Flow - Cash flow from operating activities showed a significant increase of 198.95%, totaling ¥47,642,907.07 year-to-date[5]. - Cash flow from operating activities turned positive at ¥47,642,907.07, a substantial increase of 198.95% compared to the previous year, driven by organizational restructuring[11]. - The net cash flow from operating activities was 47,642,907.07 yuan, a significant recovery from -48,147,116.27 yuan in the previous period[26]. - Cash flow from investing activities improved to ¥23,094,484.86, a 120.91% increase, mainly due to the receipt of funds from the sale of a 90% stake in a pharmaceutical company[11]. - Cash flow from financing activities decreased to -¥125,735,648.52, a decline of 180.89%, resulting from reduced borrowings and increased debt repayments[11]. Assets and Liabilities - The total assets at the end of Q3 2025 were ¥2,580,324,640.17, down 7.63% from the end of the previous year[5]. - The company's cash and cash equivalents decreased to RMB 259.09 million from RMB 307.18 million, a decline of 15.6%[18]. - Total assets decreased to RMB 2.58 billion from RMB 2.79 billion, a decline of 7.6%[20]. - The company's total liabilities decreased to RMB 1.62 billion from RMB 1.72 billion, a reduction of 6.1%[20]. - The company's equity attributable to shareholders decreased to RMB 965.43 million from RMB 1.06 billion, a decline of 9.3%[20]. Research and Development - The company's R&D expenses decreased by 27.61% to ¥32,361,278.41, primarily due to reduced investment in R&D projects[10]. - The company incurred research and development expenses of 32,361,278.41 yuan, down from 44,704,949.95 yuan, representing a reduction of approximately 27%[23]. Investment and Financing - Investment income increased significantly to ¥18,799,839.12, a rise of 615.95% compared to the previous year, primarily due to the exclusion of certain pharmaceutical companies from the financial statements[11]. - The company reported investment income of 18,799,839.12 yuan, a significant recovery from a loss of -3,643,763.21 yuan in the previous period[23]. - The company reported a significant increase in short-term borrowings by 36.15%, totaling ¥468,687,948.82[10]. - Short-term borrowings increased to RMB 468.69 million from RMB 344.24 million, an increase of 36.3%[20]. Management and Strategic Initiatives - The company has implemented a "streamlined and efficient" management restructuring, leading to reduced management and sales expenses compared to the previous year[11]. - The company is focusing on market expansion and new product development as part of its strategic initiatives[11]. - The company plans to publicly transfer 90% of its subsidiary Hubei Guangji Pharmaceutical Technology Co., Ltd. at a minimum valuation of RMB 44.7856 million[15]. - Hubei Guanghua Pharmaceutical Co., Ltd. will increase its registered capital by RMB 250 million, introducing at least two strategic investors[16]. - The company completed the transfer of 90% equity in Hubei Guangji Pharmaceutical Technology Co., Ltd. on July 7, 2025[15]. Regulatory and Compliance - The company received a warning and a fine of ¥1.5 million from the China Securities Regulatory Commission for information disclosure violations[14]. Inventory and Credit - The company's inventory stock decreased by 53.40% to ¥9,893,247.00, attributed to the failure of equity incentives to meet performance conditions[10]. - The company reported a significant increase in credit impairment losses, totaling ¥1,760,428.17, up 349.08% year-on-year[11].

Group 1 - Guangji Pharmaceutical experienced a trading halt with a daily turnover rate of 19.88% and a transaction volume of 482 million yuan, showing a price fluctuation of 4.30% [1] - The stock was listed on the Shenzhen Stock Exchange due to a daily decline deviation of -11.36%, with institutional proprietary seats net buying 3.1353 million yuan [2] - The top five trading departments had a total transaction volume of 73.0421 million yuan, with a net selling amount of 2.1292 million yuan [2] Group 2 - The main capital flow showed a net outflow of 9.6793 million yuan, with a significant single order net outflow of 18.9326 million yuan and a large order net inflow of 9.2533 million yuan [2] - Over the past five days, the main capital has seen a net outflow of 52.6351 million yuan [2] - Specific trading details indicate that institutional proprietary seats were involved in both buying and selling, with a total buy amount of 1,006.16 million yuan and a sell amount of 820.34 million yuan [2]

Core Insights - The Hubei state-owned enterprise reform sector experienced a decline of 1.68% on October 24, with Guangji Pharmaceutical leading the drop at -10.05% [1][2] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance Summary - Tianfeng Securities (601162) closed at 5.25, up 0.96%, with a trading volume of 2.7 million shares and a turnover of 1.409 billion yuan [1] - Guangji Pharmaceutical (000952) closed at 6.98, down 10.05%, with a trading volume of 683,800 shares [2] - Wuhan Holdings (600168) closed at 5.57, down 9.58%, with a trading volume of 1.3015 million shares [2] - Hubei Energy (000883) closed at 4.74, down 1.04%, with a trading volume of 482,000 shares and a turnover of 229 million yuan [1][2] Capital Flow Analysis - The Hubei state-owned enterprise reform sector saw a net outflow of 1.154 billion yuan from institutional investors, while retail investors had a net inflow of 794 million yuan [2][3] - Tianfeng Securities had a net inflow of 96.285 million yuan from institutional investors, while retail investors experienced a net outflow of 30.078 million yuan [3] - Hubei Energy had a net inflow of 44.389 million yuan from institutional investors, with retail investors seeing a net outflow of 35.716 million yuan [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.16% on October 24, with Guangji Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Nawei Technology (688690) with a closing price of 29.62, up 8.06% on a trading volume of 127,900 shares and a turnover of 370 million yuan [1] - ST Jingfeng (000908) closed at 7.32, up 5.02% with a trading volume of 228,700 shares and a turnover of 165 million yuan [1] - Major decliners included: - Guangji Pharmaceutical (000952) which fell to 6.98, down 10.05% with a trading volume of 683,800 shares and a turnover of 482 million yuan [2] - Lianhuan Pharmaceutical (600513) closed at 19.22, down 9.04% with a trading volume of 328,300 shares and a turnover of 647 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.529 billion yuan from institutional investors, while retail investors experienced a net inflow of 1.55 billion yuan [2] - The following stocks had significant capital flows: - Beida Pharmaceutical (300558) had a net inflow of 37.25 million yuan from institutional investors [3] - ST Shuangcheng (002693) saw a net inflow of 36.27 million yuan from institutional investors [3]